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Abstract With the expanding use of immunosuppressive
therapies and broad-spectrum antibiotics, Candida species
has become an increasingly important cause of infections,
particularly in the presence of anti-tumor necrosis factor-α
therapy. We report the case of a 17-year-old female with
ulcerative colitis who developed oliguric renal failure
following immunosuppressive and nephrotoxic therapy.
Although urine cultures and urinary tract imaging were
negative in the face of fungemia, renal biopsy was the key
to establishing the diagnosis of fungal tubulo-interstitial





The use of stronger biological agents for treating immune-
mediated diseases carries an increased risk of invasive
opportunistic infections. With the expanding use of immu-
nosuppressives and broad-spectrum antibiotics, fungi have
become an increasingly important cause of infections.
Candida species may have a predilection for renal
involvement, as up to 90% of patients with disseminated
candidiasis can have renal involvement at autopsy [1].
Acute renal failure in this population has been largely
reported as a complication of urinary tract obstruction from
fungal bezoar [2, 3] .O n l yas i n g l ec a s eo fa c u t e
tubulointerstitial nephritis from Candida albicans in a
patient receiving steroids and antibiotics has been reported
to date [4], but the concurrent use of nephrotoxic and
immunosuppressive agents can mask the primary cause of
acute renal failure. We report here for the first time a
pediatric case of oliguric acute renal failure in an
immunosuppressed patient with disseminated Candida
species where renal biopsy led to the diagnosis of fungal
tubulointerstitial nephritis in light of negative urine cultures
and concurrent nephrotoxic therapy.
Case report
A 17-year-old female with ulcerative colitis presented with
colonic inflammation on biopsy despite corticosteroid
treatment. Blood and urine cultures were negative, and
renal function was normal (serum creatinine 0.5 mg/dL).
Infliximab was initiated at a starting infusion dose of
5 mg/kg, and the patient developed a fever. Laboratory test
results were significant for an elevated white blood cell
count (29.3×10
3/µL) with band count (82%) in the face of
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e-mail: james.tee@alumni.utoronto.cadecreased renal function (serum creatinine 1.3 mg/dL).
Urinalysis revealed a specific gravity of 1.010, trace blood,
and no protein, leukocytes, nitrites, casts, or other sediment.
A blood culture was positive for Candida albicans. Neither
a blood-to-urine β2-microglobulin level nor plasma β-D-
glucan level were available. Stool, cerebrospinal fluid, and
urine cultures were negative. Drug therapy with intravenous
fluconazole was initiated and then subsequently switched to
caspofungin. A Doppler renal ultrasound revealed enlarged
echogenic kidneys with no evidence of abscess or hydro-
nephrosis. Magnetic resonance imaging confirmed the
absence of systemic infiltrates, and an echocardiogram
was normal. Repeat urine cultures remained negative. Renal
function continued to decline with the emergence of
oliguria (serum creatinine 7.1 mg/dL). A percutaneous
renal biopsy was performed, and hemodialysis was initiated
for fluid overload and hyperphosphatemia.
The renal biopsy showed severe active tubulointerstitial
nephritis with budding yeast forms and pseudohyphae
consistent with Candida that were visualized within the
tubules (Fig. 1). The interstitium and tubules were
infiltrated with numerous neutrophils but not eosinophils.
The tubular basement membranes were disrupted, indicat-
ing likely evolution to focal renal scarring. The glomeruli
were essentially normal. Neither vasculitis nor granulomas
were detected. Immunofluorescence microscopy was nega-
tive for immunoglobulins, complement, and fibrin.
Antifungal therapy was strengthened with the addition of
liposomal amphotericin B administered both intravenously
and via bladder irrigation. A urine culture performed after the
renal biopsy returned positive for Candida albicans several
days later. Within 1 year of discharge, the patient’s serum
creatinine had stabilized to a new baseline of 0.9 mg/dL.
Discussion
Before the renal biopsy, the differential diagnosis for acute
renal failure in this patient included medication-mediated
nephrotoxicity, an autoimmune-mediated lupus-like syn-
drome or cortical necrosis that has been reported with
infliximab, fungal nephritis (obstructive versus interstitial),
and endocarditis-associated nephritis [5, 6]. The absence of
clinical signs of lupus together with a negative anti-double
stranded DNA antibody made the classic diagnosis of
infliximab drug-induced lupus unlikely [7]. The absence of
vegetations on the echocardiogram as well as the absence
of immune-complex-mediated staining on immunohistopa-
thology ruled out endocarditis-associated nephritis. Doppler
and magnetic resonance imaging highlighted the absence of
an obstructing fungal bezoar of the urinary tract, which is
the more typical presentation of fungal-associated acute
renal failure [2, 3, 8].
As illustrated in this case, the overlapping use of anti-
tumor necrosis factor (TNF) immunosuppressive therapy
and nephrotoxic agents can complicate the diagnosis of
acute renal failure. The use of infliximab, similar to the use
of other anti-TNF-α antibody agents, presents a particularly
strong risk for severe fungal infection via its binding to
TNF, which is released by the immune system, constraining
the patient’s ability to respond to infectious stimuli [9, 10].
The U.S. Food and Drug Administration (FDA) recently
warned of an increase in reported invasive fungal infections
with the use of TNF blockers, based on primarily adult case
reports of pulmonary involvement in histoplasmosis-
endemic regions [11]. Percutaneous renal biopsy was key
to the early establishment of fungal interstitial nephritis as a
contributor to our patient’s persistent renal failure, as
standard urine cultures for fungi may take up to 4 weeks
to become positive [12]. The diffuse visible yeast forms and
pseudohyphae visualized within the tubules and interstitium
on biopsy were striking given the prior absence of positive
urinary cultures. Confirmation of a fungal cause for the
renal failure allowed for targeted augmentation of antifun-
gal therapy as well as further reductions in immunosup-
pressive therapy. This early detection and treatment of the
fungal infection in the face of TNF-blockade with signif-
icant improvement in renal function on follow-up was
consistent with other adult case studies and is supported by
a recent FDA report that over half of the patients who
experienced a delay in diagnosis ultimately died [4, 11].
In summary, the differential for acute renal failure in the
immunosuppressed fungemic pediatric patient should in-
clude fungal tubulointerstitial nephritis, particularly when
Fig. 1 Masson’s trichrome staining of the kidney reveals severe
tubulointerstitial disease and a relatively normal glomerulus. Magni-
fication ×100. Insert Fungal organisms (arrows) and neutrophils are
present in the tubules and adjacent interstitium. Periodic acid-Schiff
stain, magnification ×200
1574 Pediatr Nephrol (2009) 24:1573–1575other fungal risk factors exist, such as with concurrent anti-
TNF-α therapy. Early detection of such invasive infections
are of increasing importance with the expanded use of
TNF-blockers to the pediatric patient population, and renal
biopsy should be considered when clinical, laboratory and
radiologic methods are inconclusive.
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